Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim

The statistical dispute behind Lilly's withdrawal of its chronic pain sNDA for Cymbalta should come as no surprise to the sponsor - the issue was previewed during FDA's review of an earlier duloxetine indication, fibromyalgia